MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MannKind Corporation - Common Stock (NQ:MNKD)

4.105 +0.215 (+5.53%)
Streaming Delayed Price Updated: 3:11 PM EDT, Jul 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,743,723
Open 4.060
Bid (Size) 4.100 (17,500)
Ask (Size) 4.110 (13,400)
Prev. Close 3.890
Today's Range 3.980 - 4.230
52wk Range 2.230 - 6.510
Shares Outstanding 264,305,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
MannKind Wins FDA Approval for Furoscix ReadyFlow, Secures $50M PIPE ↗
MannKind (NASDAQ:MNKD) said the U.S. Food and Drug Administration approved Furoscix ReadyFlow, an auto-injector designed to deliver an 80-milligram dose of subcutaneous furosemide in five to 10 seconds... 
Via MarketBeat
News headline image
MannKind Announces $50 Million Private Placement
From MannKind
Via GlobeNewswire

Performance

YTD
-26.7%
-26.7%
1 Month
+4.5%
+4.5%
3 Month
+51.5%
+51.5%
6 Month
-30.5%
-30.5%
1 Year
+0.1%
+0.1%

More News

Read More
News headline image
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease
From MannKind
Via GlobeNewswire
News headline image
What This MannKind Filing Reveals About Three Years of Underperformance ↗
Via The Motley Fool
Topics Regulatory Compliance
MannKind Corp (NASDAQ:MNKD) Q1 2026 Revenue Miss and Wider EPS Loss Overshadow Strong Pipeline Progress ↗
Via Chartmill
News headline image
What This MannKind Director Sale Signals With $32.7 Million in Quarterly Royalties Revenue Potentially at Risk ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What This MannKind Sale Signals With Tyvaso Royalties at $32.7 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This MannKind Insider Stock Sale Matters Less Than a 9% Royalty at Risk ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Is MannKind a Stock to Sell After Its CEO Let Go of 363,200 Shares? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
From MannKind
Via GlobeNewswire
News headline image
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
From MannKind
Via GlobeNewswire
News headline image
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
From MannKind
Via GlobeNewswire
News headline image
MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market ↗
Via MarketBeat
News headline image
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
From MannKind
Via GlobeNewswire
News headline image
MannKind to Present at Jefferies Global Healthcare Conference
From MannKind
Via GlobeNewswire
News headline image
MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems
From MannKind
Via GlobeNewswire
News headline image
MannKind (MNKD) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
MannKind Reports First Quarter 2026 Financial Results and Provides Business Update
From MannKind
Via GlobeNewswire
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
Wednesday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
From MannKind
Via GlobeNewswire
News headline image
MannKind to Report First Quarter 2026 Financial Results on May 6, 2026
From MannKind
Via GlobeNewswire
News headline image
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces Settlement of Convertible Senior Notes
From MannKind
Via GlobeNewswire

Frequently Asked Questions

Is MannKind Corporation - Common Stock publicly traded?
Yes, MannKind Corporation - Common Stock is publicly traded.
What exchange does MannKind Corporation - Common Stock trade on?
MannKind Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MannKind Corporation - Common Stock?
The ticker symbol for MannKind Corporation - Common Stock is MNKD on the Nasdaq Stock Market
What is the current price of MannKind Corporation - Common Stock?
The current price of MannKind Corporation - Common Stock is 4.105
When was MannKind Corporation - Common Stock last traded?
The last trade of MannKind Corporation - Common Stock was at 07/24/26 03:11 PM ET
What is the market capitalization of MannKind Corporation - Common Stock?
The market capitalization of MannKind Corporation - Common Stock is 1.08B
How many shares of MannKind Corporation - Common Stock are outstanding?
MannKind Corporation - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story